Callan Family Office, LLC Actinium Pharmaceuticals, Inc. Transaction History
Callan Family Office, LLC
- $1.33 Trillion
- Q1 2025
A detailed history of Callan Family Office, LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Callan Family Office, LLC holds 23,603 shares of ATNM stock, worth $37,764. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,603Holding current value
$37,764% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
8.18MCall Options Held
51.9KPut Options Held
6.2K-
Black Rock Inc. New York, NY1.88MShares$3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$2.51 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$1.14 Million0.0% of portfolio
-
State Street Corp Boston, MA645KShares$1.03 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$798,8160.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $40.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...